Immunogenicity and safety of Haemophilus influenzae type b capsular polysaccharide tetanus conjugate vaccine (PRP-T) presented in a dual-chamber syringe with DTP

Pediatrics International

Volumn 39, Issue 6, 1997, Pages 676-680

  Kanra, GÜler ^a   YurdakÖk, Kadriye ^a   Ceyhan, Mehmet ^a   Özmert, Elif ^a   TÜrkay, Fikri ^b   Pehlivan, Tamer ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

^b Pasteur Merieux Serums and Vaccines   (Turkey)

Author keywords

Diphtheria tetanus pertussis (DTP); Dual chamber syringe; Haemophilus influenzae type b vaccine; Immunogenicity

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS TOXOID VACCINE; HAEMOPHILUS INFLUENZAE TYPE B CAPSULAR POLYSACCHARIDE TETANUS CONJUGATE VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; UNCLASSIFIED DRUG;

ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; DRUG SAFETY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; IMMUNOGENICITY; INFANT; INFLUENZA VACCINATION; NORMAL HUMAN; PRIORITY JOURNAL; SERODIAGNOSIS; SYRINGE;

ANTIBODIES, VIRAL; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B; HAEMOPHILUS VACCINES; HUMANS; INFANT; SAFETY; SYRINGES; TETANUS TOXOID; VACCINES, CONJUGATE;

EID: 0031441883     PISSN: 13288067     EISSN: 1442200X     Source Type: Journal    
DOI: 10.1111/j.1442-200X.1997.tb03666.x     Document Type: Article

References (13)

1. Robins JB, Parke JC, Scheerson R., Whinsnant JK. Quantitative measurement of ‘natural’ and immunization induced Haemophilus influenzae type b capsular polysaccharide antibodies. Pediatr. Res. 1973; 7: 103–10.
2. Robins JB, Scheerson R. Haemophilus influenzae type b: the search for a vaccine. Pediatr Infect. Dis. J. 1987; 6: 791–4.
3. Parke JC, Scheerson R. Reimer M. et al. Clinical and immunological responses to Haemophilus influenzae type b tetanus toxoid conjugate vaccine in infants injected at 3-5-9 and 18 months of age. J. Pediatr. 1991; 118: 184–90.
4. Scheerson R., Barrera O. Sutton A., Robbins JB. Preparation characterization and immunogenicity of Haemophilus influenzae type b polysaccharide protein conjugate. J. Exp. Med. 1980; 152: 361–76.
5. Ferreccio C. Clemens J. Avendano A. et al. The clinical and immunological response of Chilean infants to Haemophilus influenzae type b polysacchande-tetanus protein conjugate vaccine coadministered in the same syringe with diphtheria-tetanus toxoids-pertussis vaccine at 2, 4 and 6 months of age. Pediatr. Infect. Dis. J. 1991; 10; 764–71.
6. Eskola J. Peltola H. Takala AK et al. Efficacy of Haemophilus influenzae type b polysaccharide diphtheria toxoid. N. Engl. J. Med. 1987: 317: 717–22.
7. Clemens JD, Ferreccio C. Levine M. et al. Impact of Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine on responses to concurrently administered diphtheria-tetanus-pertussis vaccine. JAMA 1992; 267: 673–8.
8. Allen ME, Good Clinical Practice in Europe: Investigators Handbook (Revised). Rostrum Publications, Essex, 1993; 1–75.
9. Watemberg N. Dagan R. Arbelli Y. et al. Safety and immunogenicity of Haemophilus type b polysaccharide-tetanus protein conjugate vaccine, mixed in the same syringe with diphtheria-tetanus-pertussis vaccine in young infants. Pediatr. Infect. Dis. J. 1991, 10: 758–61.
10. Avendano A., Ferreccio C., Lagos R. et al Haemophilus type b polysaccharide-tetanus protein conjugate vaccine does not depress serologic responses to diphtheria, tetanus or pertussis antigens when coadministered in the same syringe at two, four and six months of age. Pediatr. Infect. Dis. J. 1993: 12: 638–43.
11. Kayhty H. Peltola H. Karanko V. Makela PH. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J. Infect. Dis. 1983: 147: 1100.
12. Mortimer EA Jr. Diphtheria toxoid. In: Plotkin S. Mortimer EA Jr (eds). Vaccines, 2nd edn. WB Saunders. Philadelphia, 1994: 41–56.
13. Barkin RM, Samuelson JS, Gotlin LP. DTP reactions and serologic response with a reduced dose schedule. J. Pediatr. 1984; 105: 189.